<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TICARCILLIN DISODIUM</span><br/>(ti-car-sill'in)<br/><span class="topboxtradename">Ticar<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">antipseudomonal penicillin</span><br/><b>Prototype: </b>Piperacillin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 g, 3 g, 6 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic injectable penicillin that is bactericidal against gram-positive and gram-negative organisms.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Susceptible organisms include <i>Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Proteus vulgaris, Enterobacter species, Haemophilus influenzae,
            Staphylococcus pneumoniae</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Primarily for gram-negative bacterial infections, bacterial septicemia, skin and soft-tissue infections, acute and chronic
         respiratory infections, genitourinary tract infection by susceptible organisms, intraabdominal infections and infections of
         the female pelvis and reproductive system.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of allergic reaction to any penicillin.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Allergy to cephalosporins; pregnancy (category C), lactation; renal impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Urinary Tract Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV</span> 200 mg/kg/d in 4 divided doses or 12 g q6h<br/><span class="rdage">Child:</span> <span class="rdroute">IM/IV</span> 50200 mg/kg/d in 4 divided doses<br/><br/><span class="indicationtitle">Systemic Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV</span> 1540 g/d in 6 divided doses (max: 40 g/d)<br/><span class="rdage">Child:</span> <span class="rdroute">IM/IV</span> 250500 mg/kg/d in 6 divided doses (max: 40 g/d)<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 150300 mg/kg/d divided q612h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Do not exceed 2 g/per injection.</li>
<li>Reconstitute each 1 g of ticarcillin with 2 mL of sterile water for injection or NS injection and use promptly. Resulting
            concentration is 1 g/2.6 mL.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p>
                  				Note: Verify correct IV concentration and rate of infusion for administration to neonates, infants, children with physician.
                  			
               </p>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute each 1 g of ticarcillin with 4 mL of sterile water for injection. Further dilute with at least 20 mL of D5W,
                  NS, or other compatible IV solution.  <span class="methodtype">Intermittent:</span> May dilute further in 50100 mL of additional compatible IV solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give slowly at a rate of 1 g over 5 min or longer.  <span class="methodtype">Intermittent:</span> Give 1 g over 30120 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<span class="classification">aminoglycosides</span>, <b>amphotericin b,</b>
<b>bleomycin,</b>
<b>chloramphenicol,</b>
<b>cytarabine,</b>
<b>doxapram,</b>
<b>lincomycin,</b>
<span class="classification">tetracyclines</span>, <b>vitamin B complex with C.</b>
<span class="incompattype">Y-site:</span>
<span class="classification">aminoglycosides</span>, <b>amphotericin B cholesteryl complex,</b>
<b>fluconazole,</b>
<b>promethazine,</b>
<b>vancomycin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Do not use solutions refrigerated longer than 72 h for multidose purposes.</li>
<li>Store dry powder at 15°30° C (59°86° F) or below.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity reactions, pain, burning, swelling at injection site; phlebitis, thrombophlebitis; superinfections. <span class="typehead">CNS:</span> Headache, blurred vision, mental deterioration, convulsions, hallucinations, seizures, giddiness, neuromuscular hyperirritability.
       <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea, nausea,</span> vomiting, disturbances of taste or smell, stomatitis, flatulence.  <span class="typehead">Hematologic:</span> Eosinophilia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia. <span class="typehead">Metabolic:</span> Hypernatremia, transient increases in serum AST, ALT, BUN, and alkaline phosphatase; increases in serum LDH, bilirubin, and
      creatinine and decreased serum uric acid. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 12 h IM. <span class="typehead">Distribution:</span> Low concentrations in CSF unless meninges are inflamed; crosses placenta; distributed into breast milk. <span class="typehead">Elimination:</span> 8090% excreted unchanged in urine within 24 h. <span class="typehead">Half-Life:</span> 67 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Obtain baseline C&amp;S tests before initiating therapy; drug may be started pending results.</li>
<li>Be aware that serious and sometimes fatal anaphylactoid reactions have been reported in patients with penicillin hypersensitivity
            or history of sensitivity to multiple allergens.
         </li>
<li>Assess IV access site frequently for vein irritation and phlebitis.</li>
<li>Discontinue ticarcillin if bleeding manifestations occur (some patients on high doses may develop hemorrhagic manifestations
            associated with abnormalities of coagulation).
         </li>
<li>Lab tests: Monitor kidney and liver functions, CBC, platelet counts, and serum electrolytes during prolonged treatment.</li>
<li>Monitor cardiac status because of the high sodium content in drug.</li>
<li>Monitor for and report for hypokalemia (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report urticaria, rashes, or pruritus to physician immediately.</li>
<li>Report frequent loose stools, diarrhea, or other possible signs of pseudomembranous colitis (see Appendix F) to physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>